Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease is a paper indexed in PICO Portal from OpenAlex.
How many citations does Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease have?
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease has 72 citations in the OpenAlex counts PICO Portal stores.
When was Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease published?
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease has 2022 year in the PICO Portal index.
What is the open-access status of Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease?
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease has gold oa status in the PICO Portal index.
What is the DOI of Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease?
The DOI for Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease is on the source record.
What is the PMID of Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease?
The PMID for Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease is on the source record.
What is the OpenAlex record for Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease?
The OpenAlex for Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease is on the source record.